Skip to main content
HLB INC. logo

HLB INC. — Investor Relations & Filings

Ticker · 028300 ISIN · KR7028300002 KO Manufacturing
Open in API
Filings indexed 553 across all filing types
Latest filing 2022-05-16 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 028300

About HLB INC.

https://www.hlb.global/

HLB INC. is a biopharmaceutical company focused on developing new global anti-cancer drugs. The company's core activities center on advancing a pipeline of novel therapeutics through its worldwide network, which includes subsidiaries like Elevar Therapeutics and Immunomic Therapeutics. In addition to its primary focus on oncology, HLB's affiliated companies are involved in other life science areas, such as developing and manufacturing in vitro diagnostic medical devices, peptide-based biomaterials, and quasi-drugs. The group also has operations in composite materials and shipbuilding, reflecting its diversified origins.

Recent filings

Filing Released Lang Actions
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for HLB Co., Ltd. covering the period from January 1, 2022, to March 31, 2022. It contains detailed company information, history, capital structure, and business descriptions, which are characteristic of a formal quarterly financial report filed with the Korean financial authorities (FSS/KRX). Q1 2022
2022-05-16 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (HLB) detailing a board decision to acquire shares in another company (Elevar Therapeutics, Inc). This type of disclosure is a standard 'Material Fact Report' (주요사항보고서) regarding the acquisition of shares or equity securities in another corporation. Since it involves a capital investment/financing activity related to a subsidiary, it falls under the 'Capital/Financing Update' category.
2022-04-27 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 1% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for HLB for the first quarter of 2022. It provides key financial highlights such as revenue and operating profit, explicitly stating these are preliminary figures (잠정치) and not yet audited. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodic financial results. Q1 2022
2022-04-25 Korean
[기재정정]사업보고서 (2021.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 37th fiscal year (2021) of HLB Co., Ltd. It contains comprehensive financial and operational information, including company history, business overview, capital changes, and management details. This is the standard Korean regulatory filing equivalent to an Annual Report (10-K). FY 2021
2022-04-22 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It specifically details a correction (정정신고) to a previously filed contract, updating the contract amount and currency conversion details. Since this is a specific regulatory disclosure regarding a material business contract and does not fit into the other specialized categories like M&A or financial reports, it is classified as a Regulatory Filing (RNS).
2022-04-08 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director appointments, and remuneration limits. This is a formal declaration of the outcomes of shareholder voting at an AGM, which fits the definition of a Declaration of Voting Results & Voting Rights Announcement.
2022-03-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.